AR111407A1 - Compuestos inhibidores de ask1 y usos de los mismos - Google Patents
Compuestos inhibidores de ask1 y usos de los mismosInfo
- Publication number
- AR111407A1 AR111407A1 ARP180100846A ARP180100846A AR111407A1 AR 111407 A1 AR111407 A1 AR 111407A1 AR P180100846 A ARP180100846 A AR P180100846A AR P180100846 A ARP180100846 A AR P180100846A AR 111407 A1 AR111407 A1 AR 111407A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- cycloalkyl
- heterocycle
- heteroaryl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cosmetics (AREA)
Abstract
Reivindicación 1: Un compuesto que tiene la estructura de fórmula (1), o una sal farmacéuticamente aceptable o solvato del mismo, en que el anillo A es un compuesto seleccionado del grupo de fórmulas (2); R¹ es un compuesto seleccionado del grupo de fórmulas (3); Z es O, S, C(=O), N(R⁸), o C(R⁹)₂; X es O ó S; R² es cicloalquilo C₃₋₆; R³ se selecciona de un grupo que consiste en hidrógeno, alquilo C₁₋₆, y cicloalquilo C₃₋₆; cada R⁴ se selecciona independientemente de un grupo que consiste en hidrógeno, halo, alquilo C₁₋₆, y cicloalquilo C₃₋₆; o un R⁴ y otro R², R³, o R⁴, junto con los átomos a los que están unidos, forman un anillo de 5 ó 6 miembros que contiene opcionalmente uno o dos heteroátomos seleccionados de O, N, y S; en que el anillo de 5 ó 6 miembros está saturado, insaturado, o es aromático; y en que el anillo de 5 ó 6 miembros está opcionalmente sustituido con uno, dos, o tres sustituyentes seleccionados del grupo que consiste en halo, -CN, alquilo C₁₋₆, -alquil C₁₋₆-OH, haloalquilo C₁₋₆, cicloalquilo C₃₋₈, heterociclo C₂₋₉, arilo C₆₋₁₀, heteroarilo C₁₋₉, -C(=O)R¹⁴, -C(=O)OR¹³, -C(=O)N(R¹³)₂, -S(=O)R¹⁴, -S(=O)₂R¹³, -S(=O)₂-N(R¹³)₂, -N(R¹³)₂, -N(R¹³)C(=O)R¹⁴, y -N(R¹³)S(=O)₂R¹³; cada R⁵ se selecciona independientemente de un grupo que consiste en halógeno y alquilo C₁₋₆; R⁵ᵃ se selecciona del grupo que consiste en hidrógeno y alquilo C₁₋₆; cada R²⁵ se selecciona independientemente de un grupo que consiste en halógeno, -CN, -OH, -OR⁶, -SR⁶, -S(=O)R⁷, -NO₂, -N(R⁶)₂, -S(=O)₂R⁷, -NHS(=O)₂R⁷, -S(=O)₂N(R⁶)₂, -C(=O)R⁷, -C(=O)OR⁶, -OC(=O)R⁷, -C(=O)N(R⁶)₂, -OC(=O)N(R⁶)₂, -NR⁶C(=O)N(R⁶)₂, -NR⁶C(=O)R⁷, -NR⁶C(=O)OR⁶, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₈, heterociclo C₂₋₉, arilo C₆₋₁₀, heteroarilo C₁₋₉, y un heteroaril C₅₋₉-cicloalquilo condensado; en que alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₈, heterociclo C₂₋₉, arilo C₆₋₁₀, heteroarilo C₁₋₉, y heteroaril C₅₋₉-cicloalquilo condensado están opcionalmente sustituidos con uno, dos, o tres sustituyentes seleccionados del grupo que consiste en halo, -CN, alquilo C₁₋₆, -alquil C₁₋₆-OH, haloalquilo C₁₋₆, cicloalquilo C₃₋₈, heterociclo C₂₋₉, arilo C₆₋₁₀, heteroarilo C₁₋₉, -C(=O)R¹⁴, -C(=O)OR¹³, -C(=O)N(R¹³)₂, -S(=O)R¹⁴, -S(=O)₂R¹³, -S(=O)₂-N(R¹³)₂, -N(R¹³)₂, -N(R¹³)C(=O)R¹⁴, y -N(R¹³)S(=O)₂R¹³; cada R⁶ se selecciona independientemente del grupo que consiste en hidrógeno, alquilo C₁₋₆, -alquil C₁₋₆-O-alquilo C₁₋₆, -alquil C₁₋₆-heterociclo C₂₋₉, -alquil C₁₋₆-heteroarilo C₂₋₉, cicloalquilo C₃₋₈, -cicloalquil C₃₋₈-fenilo, y heterociclo C₂₋₉, en que alquilo C₁₋₆, -alquil C₁₋₆-O-alquilo C₁₋₆, -alquil C₁₋₆-heterociclo C₂₋₉, -alquil C₁₋₆-heteroarilo C₂₋₉, cicloalquilo C₃₋₈, -cicloalquil C₃₋₈-fenilo, y heterociclo C₂₋₉ están opcionalmente sustituidos con uno, dos, o tres sustituyentes seleccionados del grupo que consiste en halo, -OR⁸, -SR⁸, -N(R⁸)₂, -alquilo C₁₋₆, -O-alquilo C₁₋₆, -C(=O)R¹⁴, -C(=O)OR¹³, y -N(R¹³)C(=O)R¹⁴; o dos R⁶ en el mismo heteroátomo se toman junto con el heteroátomo al que están unidos para formar un heterociclo C₂₋₉ o un heteroarilo C₂₋₉, en que heterociclo C₂₋₉ o heteroarilo C₂₋₉ están opcionalmente sustituidos con uno, dos, o tres sustituyentes seleccionados del grupo que consiste en halo, -OR⁸, -SR⁸, -N(R⁸)₂, -alquilo C₁₋₆, -O-alquilo C₁₋₆, -C(=O)R¹⁴, -C(=O)OR¹³, y -N(R¹³)C(=O)R¹⁴; cada R⁷ se selecciona independientemente del grupo que consiste en alquilo C₁₋₆, cicloalquilo C₃₋₈, y heterociclo C₂₋₉, en que cicloalquilo C₃₋₈ y heterociclo C₂₋₉ están opcionalmente sustituidos con uno, dos, o tres sustituyentes seleccionados del grupo que consiste en halo, oxo, -OR⁸, -SR⁸, -N(R⁸)₂, -alquilo C₁₋₆, -O-alquilo C₁₋₆, -C(=O)R¹⁴, -C(=O)OR¹³, y -N(R¹³)C(=O)R¹⁴; cada R⁸ se selecciona independientemente del grupo que consiste en hidrógeno y alquilo C₁₋₆; cada R⁹ se selecciona independientemente del grupo que consiste en hidrógeno, halógeno, y alquilo C₁₋₆; cada R¹³ se selecciona independientemente del grupo que consiste en hidrógeno, alquilo C₁₋₆, y cicloalquilo C₃₋₈; o dos R¹³ en el mismo heteroátomo se toman junto con el heteroátomo al que están unidos para formar un heterociclo C₂₋₉; cada R¹⁴ se selecciona independientemente del grupo que consiste en alquilo C₁₋₆ y cicloalquilo C₃₋₈; n es 0, 1, 2, 3 ó 4; p es 0, 1, 2 ó 3; y q es 0, 1 ó 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762482085P | 2017-04-05 | 2017-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111407A1 true AR111407A1 (es) | 2019-07-10 |
Family
ID=63712299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100846A AR111407A1 (es) | 2017-04-05 | 2018-04-05 | Compuestos inhibidores de ask1 y usos de los mismos |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20210087167A1 (es) |
| EP (1) | EP3606519A4 (es) |
| JP (1) | JP7196093B2 (es) |
| KR (1) | KR102665145B1 (es) |
| CN (1) | CN110730661B (es) |
| AR (1) | AR111407A1 (es) |
| AU (1) | AU2018250217B2 (es) |
| BR (1) | BR112019021021A2 (es) |
| CA (1) | CA3059107A1 (es) |
| CL (1) | CL2019002810A1 (es) |
| CO (1) | CO2019011708A2 (es) |
| CR (1) | CR20190503A (es) |
| CU (1) | CU20190080A7 (es) |
| DO (1) | DOP2019000255A (es) |
| EA (1) | EA201992299A1 (es) |
| EC (1) | ECSP19078393A (es) |
| IL (1) | IL269711B (es) |
| JO (1) | JOP20190221A1 (es) |
| MA (1) | MA49047A (es) |
| MX (1) | MX2019012013A (es) |
| NI (1) | NI201900102A (es) |
| NZ (1) | NZ758345A (es) |
| PE (1) | PE20200009A1 (es) |
| PH (1) | PH12019502288A1 (es) |
| RU (1) | RU2019134679A (es) |
| SG (1) | SG11201909155VA (es) |
| TW (1) | TWI779022B (es) |
| WO (1) | WO2018187506A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10787435B2 (en) * | 2017-01-22 | 2020-09-29 | Fuijan Cosunter Pharmaceutical Co. Ltd. | ASK1 inhibitor and preparation method and use thereof |
| MX2019013275A (es) | 2017-05-12 | 2020-07-27 | Enanta Pharm Inc | Inhibidores de la quinasa 1 reguladora de la señal de apoptosis y métodos de uso de estos. |
| WO2019136025A1 (en) | 2018-01-02 | 2019-07-11 | Seal Rock Therapeutics, Inc. | Ask1 inhibitor compounds and uses thereof |
| CN110407806B (zh) * | 2018-04-28 | 2021-08-17 | 深圳微芯生物科技股份有限公司 | 甲酰胺类化合物、其制备方法及其应用 |
| CN112312905B (zh) | 2018-05-02 | 2024-03-15 | 英安塔制药有限公司 | 含四唑的细胞凋亡信号调节激酶1抑制剂及其使用方法 |
| US10654833B2 (en) | 2018-06-28 | 2020-05-19 | Hepatikos Therapeutics, Llc | ASK1 isoindolin-1-one inhibitors and methods of use thereof |
| US10968199B2 (en) | 2018-08-22 | 2021-04-06 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US11345699B2 (en) | 2018-11-19 | 2022-05-31 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US11466033B2 (en) | 2019-03-25 | 2022-10-11 | Enanta Pharmaceuticals, Inc. | Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors |
| CN112409332B (zh) * | 2019-08-23 | 2023-12-08 | 广东东阳光药业股份有限公司 | 三氮唑衍生物及其在药物中的应用 |
| BR112022012641A2 (pt) | 2019-12-27 | 2022-09-06 | Lupin Ltd | Compostos tricíclicos substituídos |
| CN115698004A (zh) | 2020-05-01 | 2023-02-03 | 辉瑞公司 | 作为hpk1抑制剂的氮杂内酰胺化合物 |
| WO2021224818A1 (en) * | 2020-05-08 | 2021-11-11 | Pfizer Inc. | Isoindolone compounds as hpk1 inhibitors |
| WO2024020458A1 (en) * | 2022-07-20 | 2024-01-25 | Seal Rock Therapeutics, Inc. | Method of treating organ diseases or disorders with ask1 inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| TWI491606B (zh) * | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
| ES2445917T3 (es) * | 2010-02-03 | 2014-03-06 | Takeda Pharmaceutical Company Limited | Inhibidores de quinasa 1 reguladora de la señal de apoptosis |
| WO2012079022A1 (en) * | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| PL2651417T3 (pl) * | 2010-12-16 | 2017-08-31 | Calchan Limited | Pochodne pirolopirymidyny hamujące ASK1 |
| KR20170049605A (ko) * | 2014-09-24 | 2017-05-10 | 길리애드 사이언시즈, 인코포레이티드 | 간 질환의 치료 방법 |
| WO2017214359A1 (en) * | 2016-06-10 | 2017-12-14 | Venenum Biodesign Llc | Novel clostridium difficile toxin inhibitors |
| BR112019014756B1 (pt) | 2017-01-22 | 2021-08-10 | Fujian Cosunter Pharmaceutical Co., Ltd | Composto inibidor de ask1 e composição farmacêutica que o compreende |
| US10787435B2 (en) | 2017-01-22 | 2020-09-29 | Fuijan Cosunter Pharmaceutical Co. Ltd. | ASK1 inhibitor and preparation method and use thereof |
| EP3580224B1 (en) | 2017-02-07 | 2022-07-13 | Biogen MA Inc. | Ask1 inhibiting agents |
| CN109071498B (zh) | 2017-02-16 | 2021-03-30 | 四川科伦博泰生物医药股份有限公司 | 激酶抑制剂及其制备方法和用途 |
| WO2018151830A1 (en) | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Pyridinyl based apoptosis signal-regulation kinase inhibitors |
| WO2018157277A1 (en) | 2017-02-28 | 2018-09-07 | Eli Lilly And Company | Isoquinolin and naphthydrin compounds |
| KR20190126322A (ko) | 2017-03-03 | 2019-11-11 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | 아미드 유도체 억제제 및 그의 제조 방법 및 적용 |
| EP3601250A4 (en) | 2017-03-27 | 2020-11-25 | Pharmakea, Inc. | APOPTOSIS SIGNAL REGULATION KINASE 1 (ASK 1) INHIBITOR COMPOUNDS |
| WO2019055540A1 (en) * | 2017-09-13 | 2019-03-21 | D.E. Shaw Research, Llc | COMPOUNDS AS INHIBITORS OF RAS AND THEIR USE |
| US10654833B2 (en) | 2018-06-28 | 2020-05-19 | Hepatikos Therapeutics, Llc | ASK1 isoindolin-1-one inhibitors and methods of use thereof |
-
2017
- 2017-06-16 JO JOP/2019/0221A patent/JOP20190221A1/ar unknown
-
2018
- 2018-04-03 TW TW107111742A patent/TWI779022B/zh active
- 2018-04-04 PE PE2019001990A patent/PE20200009A1/es unknown
- 2018-04-04 KR KR1020197032180A patent/KR102665145B1/ko active IP Right Grant
- 2018-04-04 BR BR112019021021A patent/BR112019021021A2/pt active Search and Examination
- 2018-04-04 CN CN201880037304.1A patent/CN110730661B/zh active Active
- 2018-04-04 CU CU2019000080A patent/CU20190080A7/es unknown
- 2018-04-04 CA CA3059107A patent/CA3059107A1/en active Pending
- 2018-04-04 WO PCT/US2018/026134 patent/WO2018187506A1/en unknown
- 2018-04-04 US US16/499,075 patent/US20210087167A1/en not_active Abandoned
- 2018-04-04 NZ NZ758345A patent/NZ758345A/en unknown
- 2018-04-04 JP JP2019553366A patent/JP7196093B2/ja active Active
- 2018-04-04 CR CR20190503A patent/CR20190503A/es unknown
- 2018-04-04 EA EA201992299A patent/EA201992299A1/ru unknown
- 2018-04-04 EP EP18780760.7A patent/EP3606519A4/en active Pending
- 2018-04-04 AU AU2018250217A patent/AU2018250217B2/en active Active
- 2018-04-04 RU RU2019134679A patent/RU2019134679A/ru not_active Application Discontinuation
- 2018-04-04 MX MX2019012013A patent/MX2019012013A/es unknown
- 2018-04-04 MA MA049047A patent/MA49047A/fr unknown
- 2018-04-04 SG SG11201909155V patent/SG11201909155VA/en unknown
- 2018-04-05 AR ARP180100846A patent/AR111407A1/es unknown
- 2018-05-03 US US15/970,587 patent/US10150755B2/en active Active
-
2019
- 2019-09-26 IL IL269711A patent/IL269711B/en unknown
- 2019-10-02 CL CL2019002810A patent/CL2019002810A1/es unknown
- 2019-10-03 PH PH12019502288A patent/PH12019502288A1/en unknown
- 2019-10-03 NI NI201900102A patent/NI201900102A/es unknown
- 2019-10-04 DO DO2019000255A patent/DOP2019000255A/es unknown
- 2019-10-23 CO CONC2019/0011708A patent/CO2019011708A2/es unknown
- 2019-10-31 EC ECSENADI201978393A patent/ECSP19078393A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
| AR102177A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| AR111419A1 (es) | Compuestos fusionados de indazol piridona como antivirales | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR106806A1 (es) | Inhibidores triazol de acc y usos de los mismos | |
| AR104176A1 (es) | Inhibidores de ido (indolamina-2,3-dioxigenasa) | |
| AR113765A1 (es) | Inhibidores de la proteasa del vih | |
| AR095198A1 (es) | Derivados de triazolona de piridinilo y piridinilo fusionado | |
| AR109709A1 (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR094496A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| AR107170A1 (es) | Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih | |
| AR106100A1 (es) | Compuestos bicíclicos como inhibidores duales atx / ca | |
| AR095359A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR109964A1 (es) | Derivados de aril-sulfonamidas como bloqueadores del canal de sodio | |
| AR092347A1 (es) | Derivados de azaindol | |
| AR110298A1 (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
| AR100714A1 (es) | Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor | |
| AR108864A1 (es) | Agentes antibacterianos | |
| AR102544A1 (es) | Compuestos derivados de dihidrohidantoína como herbicidas | |
| AR106297A1 (es) | Compuestos macrocíclicos modificados como inhibidores selectivos de la quinasa cdk9 | |
| AR094497A1 (es) | Compuestos tetracíclicos sustituidos con tiofeno y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| AR095040A1 (es) | Antagonistas de h3 que contienen un núcleo estructural de fenoxipiperidina |